Conference abstract · 2019
Conference abstract
Biosimilars in emerging countries: Argentina
Abstract
Select any words in the title or abstract, or press this and choose a sentence.
The biopharmaceutical industry started in Argentina in the early eighties with the foundation of BioSidus, an R&D firm that in 1990 produced and commercialized an erythropoietin biosimilar, becoming the first in South America. Since then, the main focus of the local biopharmaceutical industry has been the production of biosimilars, including Etanercept, Filgrastim, FSH, Interferon, Interleukin-2, Molgramostim, and Somatropin, among others. Those products are priced between 30 and 70 per cent cheaper than the innovator?s product price, and the production costs reach one tenth of the originals. They are commercialized in Argentina, but between 75 and 85% is for exports to more than 30 countries in Latin America, Africa, Asia and Europe. In the absence of venture capital, and due to the high cost to the national healthcare system, the Government plays a major role in supporting projects for the generation of biopharmaceutical start-ups and partnerships between Universities, National Institutes and Pharmaceutical Firms, providing funding, incentives and tax benefits for R&D projects. One of these programs resulted this year in the opening of a plant for the production of a rituximab biosimilar and other monoclonal antibodies, the first in Latin America. Today, there are nearly 30 biopharmaceutical firms, with representations from the top ten pharma leaders in the world. Argentina is the third market in biologics of Latin America, with U$ 600 million sales in 2011 and is among the fastest growing across the globe, with an average annual growth rate of 23.5% in US-dollars since 2007
Subjects
Pharmaceutical SciencesAsk about this article
Answers come only from this article's title, abstract and keywords, each sentence pointing to where it comes from. Your question is sent to OpenAI to write the answer. Scholars Central does not store it.
Similar by topic
Conference abstract · 26 Oct 2015
Study on the registration requirements of generic applications in Latin American countries (Venezula, Chile, Colambia, Peru, Argentina & Mexico)
Conference abstract · 24 Jun 2020
Biosimilars: Comparative evaluation of Regulatory requirements of selected countries
Conference abstract · 2019
Challenges for biosimilar drug development , scale up & higher scale manufacturing : Developed and developing country landscape.
Conference abstract · 11 Jul 2016
Biosimilars; great importance and future opportunities for Asia-Pacific countries
More from this journal
The newest in Journal of Bioequivalence & Bioavailability.
Article · 5 Oct 2026
Long COVID in pediatric and young adult patients: a review of evaluation for microvascular changes, endothelial dysfunction, and arterial stiffness
Article · 12 Jun 2026
Advances in Bioavailability Through Innovative Drug Delivery Systems and Formulation Technologies
Article · 12 Jun 2026
Bioequivalence Study Design and Methodological Approaches in Generic Drug Evaluation
Conferences in this field
Upcoming conferences in this field.
Follow
New articles from what you follow go into your email digest, once you agree to alert emails.
- JournalJournal of Bioequivalence & Bioavailability
- SubjectPharmaceutical Sciences
- BylineArticles whose byline prints “Gustavo Helguera”
